Newer Anti-epileptic Drugs.
Loading...
Date
2013-11
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Need and Purpose of review: A number of newer anti-epileptic drugs have been developed in the last few years to improve the treatment
outcomes in epilepsy. In this review, we discuss the use of newer anti-epileptic drugs in children.
Methods used for locating, selecting, extracting and synthesizing data: MEDLINE search (1966-2013) was performed using terms
“newer anti-epileptic drugs”, “Oxcarbazepine”, vigabatrin”, topiramate”, “zonisamide”, “levetiracetam”, “lacosamide”, “rufinamide”,
“stiripentol”, “retigabine”, “eslicarbazepine”, “brivaracetam”, “ganaxolone” and “perampanel” for reports on use in children. Review
articles, practice parameters, guidelines, systematic reviews, meta-analyses, randomized controlled trials, cohort studies, and case
series were included. The main data extracted included indications, efficacy and adverse effects in children.
Main conclusions: Oxcarbazepine is established as effective initial monotherapy for children with partial-onset seizures. Vigabatrin is
the drug of choice for infantile spasms associated with tuberous sclerosis. Lamotrigine , levetiracetam and lacosamide are good add-on
drugs for patients with partial seizures. Lamotrigine may be considered as monotherapy in adolescent females with idiopathic generalized
epilepsy. Levetiracetam is a good option as monotherapy for females with juvenile myoclonic epilepsy. Topiramate is a good add-on drug
in patients with epileptic encephalopathies such as Lennox-Gastaut syndrome and myoclonic astatic epilepsy.
Description
Keywords
Refractory epilepsy, Epileptic encephalopathies, Oxcarbazepine, Vigabatrin, Lamotrigine, Levetiracetam
Citation
Aneja Satinder, Sharma Suvasini. Newer Anti-epileptic Drugs. Indian Pediatrics. 2013 November; 50(11): 1033-1040.